Detalles de la búsqueda
1.
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Br J Haematol
; 194(2): 365-377, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33959947
2.
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients.
Eur J Haematol
; 106(4): 563-573, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33496996
3.
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Br J Haematol
; 201(1): 162-167, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36720464
4.
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
PLoS One
; 17(1): e0262388, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015781
5.
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Hematology
; 27(1): 691-699, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666686
6.
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.
Hemasphere
; 6(6): e738, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35651713
Resultados
1 -
6
de 6
1
Próxima >
>>